CORDIS - Forschungsergebnisse der EU
CORDIS

Optimal treatment for patients with solid tumours in Europe through Artificial intelligence

Projektbeschreibung

Verbesserung der Behandlung bei Prostata-, Brust- und Lungenkrebs

Die Anzahl der Krebsfälle in Europa soll bis 2030 voraussichtlich um 14 % steigen. Entsprechend werden auch die Rufe nach innovativen Krebsbehandlungen immer lauter. Vor diesem Hintergrund wird das EU-finanzierte Projekt OPTIMA die Europäische Gesellschaft für Atemwegserkrankungen (European Respiratory Society, ERS) und die Europäische Lungenstiftung (European Lung Foundation, ELF) sowie 34 weitere Partner zusammenbringen. Ziel ist es, die erste interoperable europäische Plattform zur Generierung realer onkologischer Daten und Evidenz sowie von Instrumentarien zur Entscheidungsunterstützung für Prostata-, Lungen- und Brustkrebs zu entwickeln. OPTIMA wird bestmögliche Verfahren zur Integration von Analysen und Erkenntnissen etablieren, die auf Werkzeugen und Technologien der künstlichen Intelligenz basieren werden.

Ziel

OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individualised treatments and to innovative therapies. In that perspective, we will design, develop and deliver the first interoperable and GDPR compliant European real-world oncology data and evidence generation platform, along with decision support toolsets for prostate, lung and breast cancer. By designing this platform from the onset based on the needs of the clinicians and patients in an inclusive and sustainable way, OPTIMA aims to strengthen shared decision-making based on innovative data and AI-driven technology and tools.

To achieve our vision, we have united the key partners from other data-driven European wide oncology initiatives (PIONEER, EHDEN, HARMONY) in our project along with Europes leading clinicians in the fields of breast, prostate and lung cancer that all have leading roles in medical societies such as ERS, ESMO, and EAU. At the core of the OPTIMA project are the major guideline offices of the three indications, whilst the project is further strengthened by patient advocacy groups, well-known academic partners and 6 SMEs as partners covering the needed expertise to implement OPTIMA successfully.

The platform will build on existing open source solutions such as the OMOP-CDM, tranSMART and OHDSI ATLAS whilst developing novel AI models based on federated learning to facilitate knowledge discovery. At the start of the project, we will already have access to datasets covering over 200M people in Europe, along with data from high quality patient cohorts for AI model building. Moreover, the platform will be hosted in-kind on existing infrastructure provided by Helmholtz Institute in Germany. Finally, OPTIMA envisions sustainability of its platform through a value-based approach with various business models for commercial users.

Koordinator

STICHTING EUROPEAN UROLOGICAL FOUNDATION
Netto-EU-Beitrag
€ 822 280,00
Adresse
Mr. E.N. van Kleffenstraat 5
6842 CV Arnhem
Niederlande

Auf der Karte ansehen

KMU

Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).

Ja
Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Aktivitätstyp
Other
Links
Gesamtkosten
€ 2 800 280,00

Beteiligte (39)